BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Exosomics Siena Launches Exosome-Based Liquid Biopsy Solutions for Selective Analysis of Tumor-Derived DNA and RNA
Exosomics tumor-derived exosomes

Exosomics Siena Launches Exosome-Based Liquid Biopsy Solutions for Selective Analysis of Tumor-Derived DNA and RNA

July 23, 2018 By Cade Hildreth (CEO) Leave a Comment

  • Lonza Pharma & Biotech backs Exosomics Siena S.p.A. as they launch first products for next-generation research and diagnostic applications.

  • Exosomics Siena’s technology to bring new, highly selective solutions for cancer detection, characterization and monitoring.

Exosomics Siena tumor-derived exosomesSiena (IT) and Basel (CH), 13 July 2018 – Exosomics Siena S.p.A., a pioneer and world leader in exosome-based diagnostics, today announced the launch of its first proprietary liquid biopsy solutions, SeleCTEV™ DNA and SortEV™ RNA, for the selective isolation of tumor-derived nucleic acids from complex biofluids such as plasma or serum.

Discover class-defining bioproduction tools.

Distinct from current liquid biopsy methods, where total nucleic acids are harvested from blood with low amounts of tumor-derived genetic material, Exosomics Siena’s technologies can provide pre-analytical kits based on enriched tumor-derived exosomes and therefore enriched tumor-derived genetic material.

Exosomes are small extracellular vesicles present in all human biofluids and contain DNA, RNA and proteins originating from their parent cells. Enriching tumor exosomes, based on relevant pan-tumor markers, offers a more specific and sensitive diagnostic approach when compared with traditional liquid biopsy methods.

SeleCTEV™-DNA and SortEV™-RNA kits are novel and simple solutions that exploit Exosomics Siena’s proprietary technology to purify tumor-derived exosomes. Each technology uses a unique affinity method to select tumor-derived exosomes from which the DNA or RNA, respectively, can be extracted. At this time, the kits are released for research use only.

Rooster DevServices

Exosomics Siena is also working on the development and optimization of an early pan-cancer screening assay for asymptomatic patients projected to enter the clinical phase in 2021. The Cancer-rEVeal™ assay will demonstrate both the power of exosomes as a vehicle of multiple classes of biomarkers relevant for next-generation diagnostics and the unique expertise and approach of this growing company.

“Exosomics Siena is proud to announce the launch of the first products in its pipeline geared at enabling the next generation of liquid biopsy tests,” said Antonio Chiesi, MD, CEO of Exosomics Siena. “Our proprietary technology around tumor-exosome enrichment and isolation coupled with optimized nucleic acid extraction will allow analytical kit developers to create better assays to screen for, diagnose and monitor cancer patients.”

bitbio

Behzad Mahdavi, PhD, MBA, Chairman of the Board for Exosomics Siena and Vice President, Strategic Innovation at Lonza, said: “As part of Lonza’s wider strategy in developing exosomes, we have chosen to invest in Exosomics Siena as we believe their approach will have advantages over other non-invasive cancer tests currently on the market or in development. Because Exosomics Siena has extensive expertise in harnessing the power of exosomes in cancer diagnostics, Lonza is supporting this innovative company as they develop a platform that will greatly benefit patients.”

5/5 - (3 votes)

Filed Under: Exosomes Tagged With: exosomes, Exosomics Siena, Lonza

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Featured Posts

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

iPSC derived cell therapeutics

The Pipeline for iPSC-Derived Cell Therapeutics in 2022

Stem cell companies

List of Stem Cell Companies Worldwide (2022)

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.